August 15, 2024 – Pfizer Inc. introduced optimistic topline security and immunogenicity outcomes from substudy B of the continued pivotal Part 3 medical trial (NCT05842967) MONET cash (HSV I Mammunition ONResearch for adults Ts at increased danger of extreme illness), evaluating two doses of the ABRYSVO vaccine in immunocompromised adults 18 years of age and older who’re in danger for growing extreme respiratory syncytial virus (RSV)-associated decrease respiratory tract illness (LRTD). ABRYSVO was properly tolerated through the trial, with a security profile per findings from different research of the vaccine.

Adults with immunocompromised situations are at elevated danger of growing RSV-LRTD. Substudy B of the MONeT trial was performed to guage the security and immunogenicity of two doses of ABRYSVO administered one month aside in 4 teams of immunocompromised adults: these with non-small cell lung most cancers, these present process hemodialysis for end-stage renal illness, these with an autoimmune inflammatory illness receiving energetic immunomodulator remedy, and stable organ transplant recipients. Of the 203 adults enrolled within the substudy, roughly half have been between the ages of 18 and 59 and roughly half have been 60 years of age or older.

Extra info